Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1183/13993003.02493-2016 http://scihub22266oqcxt.onion/10.1183/13993003.02493-2016 C5593379!5593379 !28818881     free     free     free Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\28818881 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Eur+Respir+J 2017 ; 50 (2 ): ä Nephropedia Template TP {{tp|p=28818881 |t=2017. Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension |pdf=|usr=}}{{28818881 }} gab.com Text Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension JO: Eur Respir J http://www.kidney.de/pget.php?&tw=1&pmid=28818881 #FOAvip Patients with connective tissue disease-associated pulmonary arterial hypertension (PAH-CTD) have a poor prognosis compared with other aetiologies. The underlying CTD can influence treatment response and outcomes. We characterised the GRIPHON study PAH-CTD subgroup and evaluated response to selexipag.Of 334 patients with PAH-CTD, PAH was associated with systemic sclerosis (PAH-SSc) in 170, systemic lupus erythematosus (PAH-SLE) in 82 and mixed CTD/CTD-other in 82. For the primary composite endpoint of morbidity/mortality, hazard ratios (HR) and 95% CI were calculated using Cox proportional hazard models.Compared with the overall GRIPHON population, the CTD subgroup was slightly older with a greater proportion of females and shorter time since diagnosis. Patients with PAH-SSc appeared to be more impaired at baseline, with a more progressive disease course. The converse was observed for PAH-SLE. Selexipag reduced the risk of composite morbidity/mortality events in patients with PAH-CTD by 41% (HR 0.59; 95% CI 0.41-0.85). Treatment effect was consistent irrespective of baseline PAH therapy or CTD subtype (interaction p=0.87 and 0.89, respectively). Adverse events were predominately prostacyclin-related and known for selexipag treatment.GRIPHON has allowed the comprehensive characterisation of patients with PAH-CTD. Selexipag delayed progression of PAH and was well-tolerated among PAH-CTD patients, including those with PAH-SSc and PAH-SLE. Twit Text FOAVip Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension ????Eur Respir J http://www.kidney.de/pget.php?&tw=1&pmid=28818881 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28818881 #FOAvip English Wikipedia <ref>{{Cite pmid|28818881 }}</ref> Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension #MMPMID28818881 Gaine S ; Chin K ; Coghlan G ; Channick R ; Di Scala L ; Galiè N ; Ghofrani HA ; Lang IM ; McLaughlin V ; Preiss R ; Rubin LJ ; Simonneau G ; Sitbon O ; Tapson VF ; Hoeper MM Eur Respir J 2017[Aug]; 50 (2 ): ä PMID28818881 show ga Patients with connective tissue disease-associated pulmonary arterial hypertension (PAH-CTD) have a poor prognosis compared with other aetiologies. The underlying CTD can influence treatment response and outcomes. We characterised the GRIPHON study PAH-CTD subgroup and evaluated response to selexipag.Of 334 patients with PAH-CTD, PAH was associated with systemic sclerosis (PAH-SSc) in 170, systemic lupus erythematosus (PAH-SLE) in 82 and mixed CTD/CTD-other in 82. For the primary composite endpoint of morbidity/mortality, hazard ratios (HR) and 95% CI were calculated using Cox proportional hazard models.Compared with the overall GRIPHON population, the CTD subgroup was slightly older with a greater proportion of females and shorter time since diagnosis. Patients with PAH-SSc appeared to be more impaired at baseline, with a more progressive disease course. The converse was observed for PAH-SLE. Selexipag reduced the risk of composite morbidity/mortality events in patients with PAH-CTD by 41% (HR 0.59; 95% CI 0.41-0.85). Treatment effect was consistent irrespective of baseline PAH therapy or CTD subtype (interaction p=0.87 and 0.89, respectively). Adverse events were predominately prostacyclin-related and known for selexipag treatment.GRIPHON has allowed the comprehensive characterisation of patients with PAH-CTD. Selexipag delayed progression of PAH and was well-tolerated among PAH-CTD patients, including those with PAH-SSc and PAH-SLE. |*Acetamides/administration & dosage/adverse effects [MESH] |*Hypertension, Pulmonary/diagnosis/drug therapy/etiology/mortality [MESH] |*Pyrazines/administration & dosage/adverse effects [MESH] |Adult [MESH] |Antihypertensive Agents/administration & dosage/adverse effects [MESH] |Disease Progression [MESH] |Double-Blind Method [MESH] |Female [MESH] |Humans [MESH] |Lupus Erythematosus, Systemic/*complications [MESH] |Male [MESH] |Middle Aged [MESH] |Outcome Assessment, Health Care [MESH] |Risk Assessment [MESH] |Scleroderma, Systemic/*complications [MESH]Selexipag for the treatment of connective tissue disease-associated pu(epmc).pdf DeepDyve Pubget Overpricing